Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Single nucleotide polymorphisms in tobacco metabolism and DNA repair genes and prognosis in resected non-small-cell lung cancer.

Campayo M, Viñolas N, Navarro A, Carcereny E, Casas F, Gel B, Diaz T, Gimferrer JM, Marrades RM, Ramirez J, Monzo M.

J Surg Res. 2011 May 1;167(1):e5-12. doi: 10.1016/j.jss.2011.01.007.

PMID:
21324488
2.

An association between DNA repair gene polymorphisms and survival in patients with resected non-small cell lung cancer.

Butkiewicz D, Rusin M, Sikora B, Lach A, Chorąży M.

Mol Biol Rep. 2011 Nov;38(8):5231-41. doi: 10.1007/s11033-010-0674-1.

PMID:
21188533
3.

Polymorphisms in apoptosis-related genes and survival of patients with early-stage non-small-cell lung cancer.

Lee EB, Jeon HS, Yoo SS, Choi YY, Kang HG, Cho S, Cha SI, Choi JE, Park TI, Lee BH, Park RW, Kim IS, Kang YM, Kim CH, Jheon S, Jung TH, Park JY.

Ann Surg Oncol. 2010 Oct;17(10):2608-18. doi: 10.1245/s10434-010-1082-4.

PMID:
20422457
4.

Polymorphisms of DNA repair genes and risk of non-small cell lung cancer.

Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, Stangeland L, Phillips DH, Canzian F, Haugen A.

Carcinogenesis. 2006 Mar;27(3):560-7.

PMID:
16195237
5.

Lung cancer susceptibility and prognosis associated with polymorphisms in the nonhomologous end-joining pathway genes: a multiple genotype-phenotype study.

Tseng RC, Hsieh FJ, Shih CM, Hsu HS, Chen CY, Wang YC.

Cancer. 2009 Jul 1;115(13):2939-48. doi: 10.1002/cncr.24327.

6.

Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer.

Huang CL, Taki T, Adachi M, Konishi T, Higashiyama M, Kinoshita M, Hadama T, Miyake M.

Int J Oncol. 1998 Mar;12(3):553-63.

PMID:
9472092
7.

Potentially functional polymorphisms in cell cycle genes and the survival of non-small cell lung cancer in a Chinese population.

Ma H, Chen J, Pan S, Dai J, Jin G, Hu Z, Shen H, Shu Y.

Lung Cancer. 2011 Jul;73(1):32-7. doi: 10.1016/j.lungcan.2010.11.001.

PMID:
21145615
8.

Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma.

Yin Z, Zhou B, He Q, Li M, Guan P, Li X, Cui Z, Xue X, Su M, Ma R, Bai W, Xia S, Jiang Y, Xu S, Lv Y, Li X.

BMC Cancer. 2009 Dec 15;9:439. doi: 10.1186/1471-2407-9-439.

9.

ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.

Lee KH, Min HS, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Kim YT, Kim TY, Heo DS, Bang YJ, Sung SW, Kim JH.

Lung Cancer. 2008 Jun;60(3):401-7.

PMID:
18036700
10.

Cyclooxygenase-2 genetic variants are associated with survival in unresectable locally advanced non-small cell lung cancer.

Bi N, Yang M, Zhang L, Chen X, Ji W, Ou G, Lin D, Wang L.

Clin Cancer Res. 2010 Apr 15;16(8):2383-90. doi: 10.1158/1078-0432.CCR-09-2793.

11.

Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival.

Brabender J, Usadel H, Danenberg KD, Metzger R, Schneider PM, Lord RV, Wickramasinghe K, Lum CE, Park J, Salonga D, Singer J, Sidransky D, Hölscher AH, Meltzer SJ, Danenberg PV.

Oncogene. 2001 Jun 14;20(27):3528-32.

12.

Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.

De Petris L, Orre LM, Kanter L, Pernemalm M, Koyi H, Lewensohn R, Lehtiö J.

Lung Cancer. 2009 Mar;63(3):410-7. doi: 10.1016/j.lungcan.2008.06.003.

PMID:
18620780
13.

Potentially functional polymorphisms in DNA repair genes and non-small-cell lung cancer survival: a pathway-based analysis.

Dong J, Hu Z, Shu Y, Pan S, Chen W, Wang Y, Hu L, Jiang Y, Dai J, Ma H, Jin G, Shen H.

Mol Carcinog. 2012 Jul;51(7):546-52. doi: 10.1002/mc.20819.

PMID:
21739480
14.

Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.

Huang C, Taki T, Adachi M, Konishi T, Higashiyama M, Miyake M.

Oncogene. 1998 May 14;16(19):2469-77.

15.

Prognosis of the surgical treatment of patients with non-small cell lung cancer (NSCLC)--relation to DNA ploidy.

Gawrychowski J, Lackowska B, Gabriel A.

Eur J Cardiothorac Surg. 2003 Jun;23(6):870-7; discussion 877.

PMID:
12829060
16.

Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.

Giachino DF, Ghio P, Regazzoni S, Mandrile G, Novello S, Selvaggi G, Gregori D, DeMarchi M, Scagliotti GV.

Clin Cancer Res. 2007 May 15;13(10):2876-81.

17.

Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.

Zhou C, Ren S, Zhou S, Zhang L, Su C, Zhang Z, Deng Q, Zhang J.

Jpn J Clin Oncol. 2010 Oct;40(10):954-60. doi: 10.1093/jjco/hyq071.

PMID:
20462983
18.

[Prognosis after complete surgical resection for non-small cell lung cancer based on the staging classification].

Pfannschmidt J, Muley T, Hoffmann H, Bülzebruck H, Dienemann H.

Dtsch Med Wochenschr. 2006 Nov 24;131(47):2643-8. German.

PMID:
17109272
19.

Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC).

Tanaka F, Miyahara R, Ohtake Y, Yanagihara K, Fukuse T, Hitomi S, Wada H.

Eur J Cardiothorac Surg. 1998 Sep;14(3):256-62; discussion 263-4.

PMID:
9761434
20.

Abasic sites and survival in resected patients with non-small cell lung cancer.

Zhao H, Shen J, Deininger P, Hunt JD.

Cancer Lett. 2007 Feb 8;246(1-2):47-53.

PMID:
16519994
Items per page

Supplemental Content

Support Center